This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study
will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to
severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54
subjects completers through Week 48. AA subjects must have evidence of hair regrowth within
the last 7 years of their last episode of hair loss; and have screening IgE ≥ 200 and/or have
personal and/or familial history of atopy.
Subjects will be randomized (2:1) to either receive weekly dupilumab or placebo for 48 weeks,
with all subjects completing participation through Week 48 receiving an additional 48 weeks
of dupilumab (through Week 96).